Immupharma PLC Result of Retail Offer and Director Shareholding (6396L)
September 07 2023 - 2:00AM
UK Regulatory
TIDMIMM
RNS Number : 6396L
Immupharma PLC
07 September 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED
STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR
ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO
ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR
BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE
IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
7 September 2023
ImmuPharma Plc
("ImmuPharma" or the "Company")
Result of Retail Offer and Director Shareholding
ImmuPharma Plc is pleased to announce that further to the
Company's announcement at 7:02 a.m. on 31 August 2023, the Company
has conditionally raised gross proceeds of GBP130,683 through the
issue of 6,534,150 New Ordinary Shares at a price of 2 pence to
existing retail investors of the Company, via the Winterflood
Retail Access Platform ("WRAP"), in addition to the GBP1.35 million
raised in the Subscription and Direct Subscription.
An application has been made to the London Stock Exchange for
the 6,534,150 new Ordinary Shares to be admitted to trading on AIM.
Admission is expected to take place, and dealings on AIM in the
Retail Offer Shares are expected to commence, at 8.00 a.m. on or
around 12 September 2023.
Director Dealing
Lisa Baderoon, Director, subscribed for 1,000,000 Retail Offer
Shares in the Retail Offer. Following Admission, Lisa Baderoon's
shareholding will be 1,583,963 Ordinary Shares comprising 0.38% of
the issued share capital.]
Total Voting Rights
Following Admission, the Company will have 416,437,265 Ordinary
Shares in issue. Since the Company currently holds no shares in
treasury, the total number of voting rights in the Company will
therefore be 416,437,265. These figures may therefore be used by
Shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the share capital of the Company
under the FCA's Disclosure Guidance and Transparency Rules.
Capitalised terms used but not defined in this announcement have
the same meanings as set out in the announcement of the Company at
7:02 a.m. on 31 August 2023.
For Further Information
ImmuPharma plc
Tim McCarthy, Chief Executive
Officer
Lisa Baderoon, Head of Investor +44 (0) 207 206 2650
Relations + 44 (0) 7721 413496
Stanford Capital Partners
Patrick Claridge
Bob Pountney +44 (0) 203 650 3650
SPARK Advisory Partners Limited +44 (0) 203 368 3554
Neil Baldwin +44 (0) 113 370 8974
Winterflood Retail Access Platform WRAP@winterflood.com
Alex Skrine, Head of Electronic
Trading +44 (0) 20 3100 0000
Phoebe Pankhurst, Corporate
Finance
Haris Khawaja, Corporate Finance
Further information on the Company can be found on its website
at https://www.immupharma.co.uk/
The Company's LEI is 213800VZKGHXC7VUS895
Details of t he p erson disc harging managerial responsib
1 ilities / p erson closely associated
a) Name Lisa Baderoon
-------------------------- ----------------------------------------
Reason for notification
2
--------------------------------------------------------------------
a) Position / status Director
-------------------------- ----------------------------------------
b) I nitial notification Initial
/Amendment
-------------------------- ----------------------------------------
Details of t he issu er, e mission allow a n ce m a r k
3 et participan t, au ct ion plat for m, au ction eer or auc
tion monitor
--------------------------------------------------------------------
a) Name ImmuPharma Plc
-------------------------- ----------------------------------------
b) LEI 213800VZKGHXC7VUS895
-------------------------- ----------------------------------------
Details of t he t ransact ion (s): section to be re p eated
4 for ( i) e a ch type of instr u m e n t; (ii) each type of
transac tion; (iii) each date; and ( iv) each place w h ere
transactions have b een condu cted
--------------------------------------------------------------------
a) Description of the Ordinary shares of 1p (GBP0.01) each in
financial instrument, the capital of ImmuPharma plc
t ype of instrument ISIN GB0033711010
I d e ntification
code
-------------------------- ----------------------------------------
Nature of the transaction Subscription in retail offer
-------------------------- ----------------------------------------
Price(s) and volumes(s) Price(s) Volume(s)
GBP0.02 1,000,000
----------
-------------------------- ----------------------------------------
d) Aggregated information
- Aggregated volume 1,000,000
- Aggregated price GBP0.02
-------------------------- ----------------------------------------
e) Date of the transaction 7 September 2023
-------------------------- ----------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- ----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCNKABNDBKBCCK
(END) Dow Jones Newswires
September 07, 2023 02:00 ET (06:00 GMT)
Immupharma (AQSE:IMM.GB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immupharma (AQSE:IMM.GB)
Historical Stock Chart
From Apr 2023 to Apr 2024
